Overview

A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of ELND002 in patients with multiple sclerosis (MS) after participation in study MS103.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Elan Pharmaceuticals
Criteria
Inclusion Criteria:

- This study is open only to subjects who have completed the week 12 visit in study
ELND002-MS103 while taking their assigned dose of study drug.

Exclusion Criteria:

- Subject has no new medical contraindications to continue participation in the study.